The evidence mainly from pre-clinical studies suggesting that ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), drugs often prescribed for CVD, kidney, and metabolic diseases, might up-regulate circulating and tissue expression of ACE2 (16–20), raised the question whether those therapies increase SARS-CoV-2 infectivity and COVID-19 severity. The gene discussed is ACE2; the disease is metabolic disease.